Collections

The AACR Annual Meeting is where new modalities and targets debut, each April.

AACR Project GENIE is real-world tumour sequencing data shared by leading cancer centres.

ADC Review covers everything ADC: deals, payload chemistry, and monthly pipeline summaries.

ADCdb and ADC Review are where to track the hundreds of ADCs in trials, with target, payload, and linker.

A childhood-cancer charity started by a four-year-old patient's lemonade stand that now funds hundreds of grants and runs an open-science data lab for paediatric cancer genomics.

America's answer to UK Biobank, built for diversity.

The American Cancer Society is the largest US cancer charity: the source of the widely quoted annual US cancer statistics, screening recommendations that differ from the USPSTF in places, and plain-language patient guides for every cancer.

Plain-language patient information, with ASCO's clinical review behind it.

Annals of Oncology is the European counterpart of JCO, and the place ESMO Congress abstracts are published.

Arc's growing library of cell data, the fuel for virtual cell models.

ASCO guidelines are the American oncology society's guidelines, strongest on supportive care, survivorship, biomarker testing and resource-stratified recommendations for lower-income settings, complementing NCCN's algorithms.

ASCO's own daily read, best during the Annual Meeting.

The primary record of what was presented at ASCO meetings each year.

The ASH Annual Meeting is December's blood-cancer summit, bringing CAR-T, bispecifics, menin, BTK, and myeloma news.

The ASTRO Annual Meeting is where hypofractionation, SBRT, protons, FLASH, and MR-guided radiotherapy results appear.

A GitHub list of every cancer variant database, maintained by the community.

BioCentury writes analysis for people who make decisions about pipelines.

BioPharma Dive offers clean, free industry reporting and is good for deal and approval context.

bioRxiv is where new targets and mechanisms surface first, before peer review.

For blood cancers, this and ASH's December meeting are the centre of gravity.

The Breast Cancer Research Foundation publishes research-literate breast cancer news for a general audience.

The biology behind the targets: where new dependencies and resistance mechanisms are first described.

Cancer Discovery is the best single journal for seeing what will be in the clinic in five years.

Find a mouse or dish model that matches a tumour type or mutation.

Deep preclinical biology, one step before Cancer Discovery.

Cancer Research UK's About Cancer pages give clear UK patient information, including NHS treatment pathways.

CancerNetwork publishes daily practice-oriented news across solid and haematologic cancers.

cBioPortal lets you browse the mutations, copy number, and expression of tens of thousands of tumours without writing code.

CIViC is an open, Wikipedia-style database of what cancer mutations mean for treatment.

Clinical Cancer Research is the best place to read early-phase trial detail and biomarker validation.

ClinicalTrials.gov is the master list of clinical trials. Every trial on this site links to its record.

Whether a genetic variant is thought to cause disease, according to the labs that have seen it.

The Colorectal Cancer Alliance is the largest US colorectal cancer patient organisation, focused on screening uptake from age 45, young-onset disease and connecting patients with biomarker-matched trials.

COSMIC is the encyclopaedia of cancer mutations, including the definitive list of cancer genes.

CPTAC measures the proteins, not just the genes, of thousands of tumours.

CSCO guidelines are China's national oncology guidelines, notable for grading recommendations by both evidence and affordability, and for covering Chinese-developed drugs (PD-1 inhibitors, ADCs) and cancers common in China (nasopharyngeal, oesophageal, liver, gastric) earlier than Western guidelines.

CELLxGENE and the Human Cell Atlas hold single-cell data from healthy and diseased tissue, browsable and downloadable.

Which genes each cancer cell line cannot live without. The map of synthetic-lethal targets.

Dimensions connects papers to the grants and trials behind them.

DrugBank and ChEMBL hold the chemistry and mechanism of every drug and most tool compounds.

The EMA's CHMP highlights show Europe's approval pipeline one month ahead of European Commission decisions.

Endpoints News is the fastest read on what biotech and pharma are doing in oncology, deal by deal.

The ESMO guidelines are Europe's treatment algorithms, and the ESMO-MCBS scores how much each new drug actually helps.

ESMO Congress is the autumn counterpart to ASCO, where many phase 3 firsts now land.

ESMO Open carries free-to-read ESMO content, including many guideline updates.

The EU Clinical Trials Register and CTIS are Europe's trial registry, complementing ClinicalTrials.gov for EU-only studies.

Evaluate Vantage forecasts which drugs and modalities will matter commercially in the next decade.

The FDA's oncology approval notifications are the official record of what is approved for what.

Fierce Biotech is where trial failures get reported plainly.

Real-world evidence at scale: what happened to patients with a given genomic profile on a given treatment.

GLOBOCAN is the world's cancer numbers: incidence and mortality estimates for 185 countries and 36 cancers.

Healio Hematology/Oncology publishes clinician-facing daily news with good approval and lifestyle-risk coverage.

The Human Protein Atlas shows where in the body each protein is found, which tells you whether an ADC target is safe.

JAMA Oncology is good for real-world outcomes, costs, disparities, and critical secondary analyses.

The JSMO and JSCO guidelines are Japan's oncology guidelines, especially strong for gastric, oesophageal, liver and biliary cancers where Japanese trials set global standards (D2 gastrectomy, S-1, endoscopic resection), and for Japan's own approvals through PMDA.

JNCI covers screening and population science, including the long-running US cancer statistics reports.

The Journal of Clinical Oncology is where ASCO publishes its guidelines and most US cooperative-group trial results.

The Leukemia & Lymphoma Society is the main US blood-cancer charity, unusual for running its own precision-medicine trials (Beat AML, PedAL) and investing directly in biotech, alongside co-pay assistance and one-to-one information specialists.

Congress results translated for people with breast cancer, fast and accurately.

LUNGevity is the largest US lung cancer charity, focused on making sure every patient gets comprehensive biomarker testing and access to targeted therapy and trials, with a screening-advocacy partner in GO2.

The Lymphoma Research Foundation is the largest US lymphoma-specific charity, with plain-language guides for over 20 lymphoma subtypes and a research programme focused on mantle cell and adolescent/young adult lymphoma.

Macmillan Cancer Support covers the practical side of cancer: money, work, coping, and where to get help.

medRxiv posts trial results and real-world analyses weeks to months before journals. Nothing on it has been peer reviewed.

Medscape Oncology publishes broad clinician news with continuing-education tie-ins.

A melanoma research funder created in 2007 by the Milken family that backed early immunotherapy and targeted-therapy work and now focuses on rare melanoma subtypes and resistance.

A myeloma foundation that built the most important open genomic dataset in the disease (CoMMpass) and funded much of the science behind today's therapies; also a patient support and navigation resource.

The National Brain Tumor Society is the largest US brain tumour nonprofit, notable for helping create GBM AGILE, the adaptive platform trial that tests many glioblastoma drugs at once, and for its advocacy on FDA endpoints for brain tumours.

Nature Briefing: Cancer is one email a week that catches the papers you missed.

Nature Cancer is Nature's dedicated cancer journal, heavier on mechanism than on trials.

The Nature Index shows which institutions publish the most top-tier research. It is the best public proxy for university output in cancer science.

Where AI-in-medicine trials, personalised vaccines, and cell-therapy firsts get published.

The algorithms US oncologists follow. If a drug is in NCCN, insurers usually pay.

NCI CDAS holds the lung screening trial images that trained Sybil and most lung-nodule AI.

The Imaging Data Commons is TCIA in the cloud, ready for large-scale model training.

The NCI's PDQ summaries are the most reliable free, plain-language explanation of each cancer's treatment.

NCI-designated cancer centres are the US government's list of the cancer centres that meet its research and care standards.

Where the biggest trial results appear first. If a drug changes practice, the paper is usually here.

The Newsweek/Statista ranking is the most-cited global hospital ranking for cancer care. OnCo uses it as one input to its institution table.

The UK body that decides which cancer treatments the NHS pays for, publishing detailed appraisals of cost per quality-adjusted life year for each drug, plus clinical guidelines. Its decisions are widely read as an independent view of value.

NICE technology appraisals say whether the NHS will pay, and why. They are the most transparent HTA record in the world.

Open-access home for genomics and AI-in-oncology papers.

OncLive delivers fast approval and readout news with key opinion leader interviews.

OncoDaily publishes high-volume daily oncology news with international reach.

Tells you, for a given mutation, whether an approved or investigational drug exists and how strong the evidence is.

Open Targets scores how strongly each gene is linked to each disease, with the evidence behind it.

The Ovarian Cancer Research Alliance is the largest US ovarian cancer organisation, born from the merger of research and patient-support charities; it funds research and campaigns for universal genetic testing and prevention by salpingectomy given that screening does not work.

PanCAN is the patient hub for pancreatic cancer, including trial navigation.

PanCAN is the leading pancreatic cancer patient organisation; it pioneered free tumour molecular profiling for patients (Know Your Tumor) and runs an adaptive platform trial for a disease with few options.

The exam papers every pathology model is graded on.

Michael Milken's prostate cancer foundation, which funded the science behind abiraterone, enzalutamide and PSMA therapy and runs a precision-oncology network in US veterans' hospitals.

PubMed and Europe PMC together form the searchable index of the biomedical literature; every claim here should trace back to something in them.

The San Antonio Breast Cancer Symposium packs the year's breast cancer evidence into one week every December.

SCImago publishes a bibliometric ranking of institutions specifically in oncology.

SEER records how many people in the US get each cancer and how long they live, by stage, age, race, and year.

Semantic Scholar offers free literature search with machine-generated summaries and citation context.

The SNMMI Annual Meeting is the theranostics meeting, held each June.

A head-shaving fundraiser that became the largest charitable funder of children's cancer research in the US, underwriting much of the cooperative-group trial infrastructure that treats most American children with cancer.

STAT News has the best-written reporting on the science and business of cancer, with real scepticism.

Susan G. Komen is the best-known breast cancer charity, a major funder of research and a large provider of patient navigation and financial assistance, with a patient-driven research registry that shares data for metastatic breast cancer research.

Tahoe-100M is the biggest single-cell dataset ever released, built to teach AI how cancer cells respond to drugs.

Targeted Oncology is OncLive's sibling with a biomarker and targeted-therapy focus.

The reference atlas of cancer genomes that most cancer biology since 2008 is built on.

The ASCO Post gives reliable, clinician-written summaries of the trials that matter, usually within days.

The public archive of cancer scans that most radiology AI is trained and tested on.

The Cancer Letter tells the inside story of cancer institutions and policy. Nobody else covers NCI and the centres this closely.

The Lancet Oncology is the other home of practice-changing trials, with a stronger European and global-health voice.

The Therapeutic Target Database lists every protein anyone has tried to drug, and what they tried.

Support and information built specifically for triple-negative breast cancer.

UK Biobank is the richest population cohort for linking genes, blood and imaging to who later develops cancer.

UroToday is the prostate, bladder, and kidney cancer feed, including PSMA and radioligand news.